DNM1 and acute lymphoblastic leukemia: Chew et al. (2020) report on blocking CME as an effective strategy to improve the clinical response to antibody dependent cellular cytotoxicity mediating antibodies in humans; Tremblay et al. (2020) report that the dynamin inhibitor, dynole 34-4 is highly synergistic with existing chemotherapy in mouse models of T-ALL and AML; Powell et al. (2021) report that endocytosis inhibition attenuates inflammatory pain like behaviour; and Jensen et al. (2017) also reported on an endocytosis mediated effect as a viable therapeutic target for prolonged pain relief.